



=> d 11  
L1 HAS NO ANSWERS  
L1 STR



VPA 22-16/18/19 U

NODE ATTRIBUTES:

DEFAULT MLEVEL IS ATOM  
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:

RSPEC 1 19 13  
NUMBER OF NODES IS 24

STEREO ATTRIBUTES: NONE

=> s 11 ful

FULL SEARCH INITIATED 15:10:37 FILE 'REGISTRY'  
FULL SCREEN SEARCH COMPLETED - 32191 TO ITERATE

100.0% PROCESSED 32191 ITERATIONS  
SEARCH TIME: 00.00.01

305 ANSWERS

L3 305 SEA SSS FUL L1

=> fil caplus  
COST IN U.S. DOLLARS  
FULL ESTIMATED COST

SINCE FILE ENTRY	TOTAL SESSION
156.68	156.89

FILE 'CAPLUS' ENTERED AT 15:10:42 ON 23 DEC 2004  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 23 Dec 2004 VOL 141 ISS 26  
FILE LAST UPDATED: 22 Dec 2004 (20041222/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s 13  
L4 5 L3

=> d bib abs 1-5

L4 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2004 ACS on STN  
AN 2004:344622 CAPLUS  
DN 140:357212  
TI Preparation of substituted anilinic piperidines as MCH selective antagonists  
IN Marzabadi, Mohammad R.; Wetzel, John; Deleon, John E.; Jiang, Yu; Chen, Chien-An; Lu, Kai  
PA Synaptic Pharmaceutical Corporation, USA  
SO U.S., 394 pp.  
CODEN: USXXAM  
DT Patent  
LA English  
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 6727264	B1	20040427	US 2002-188434	20020703
PRAI US 2001-303091P	P	20010705		
OS US 2002-346997P	P	20020109		
OS MARPAT 140:357212				

GI

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

AB The title compds. [I (R1 = H, alkyl, aryl, etc.; R2 = alkyl, cyclopropyl; R3 = (un)substituted (hetero)aryl; A = H, F, Cl, Br, CN, etc.; X = O, NH; n = 0-5), II (W = III, IV (wherein R1 = H, Me, Et; X = O, NR3, CO, a bond; Y = H, (hetero)aryl; R3 = H, (hetero)aryl); R2 and A as above)] which are selective antagonists for melanin concentrating hormone-1 (MCH1) receptors, were prepared. Thus, reacting 2-methyl-N-[3-(4-piperidinyl)phenyl]propanamide (preparation given) with 4-chloro-3',4'-dimethylbutyrophenone in the presence of K2CO3 and NaI in DMF afforded 80% V which showed Ki of 3.9 nM in cloned rat MCH1 binding assay.

RE.CNT 25 THERE ARE 25 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2004 ACS on STN  
AN 2004:162444 CAPLUS  
DN 140:212060  
TI DNA encoding a human melanin concentrating hormone receptor (MCH1) and uses thereof and preparation of 4-phenylpiperidine derivatives as human MCH1 receptor antagonists  
IN Salon, John A.; Laz, Thomas M.; Nagorny, Raisa; Wilson, Amy E.; Craig, Douglas A.  
PA USA  
SO U.S. Pat. Appl. Publ., 180 pp., Cont.-in-part of U.S. Ser. No. 899,732.  
CODEN: USXXCO  
DT Patent  
LA English  
FAN.CNT 4

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 2004038855	A1	20040226	US 2003-341751	20030114

WO 2000039279

A2 20000706

WO 1999-US31169

19991230

WO 2000039279

A3 20001102

W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

US 2003082623

A1 20030501

US 2001-899732

20010705

WO 2004064774

A2 20040805

WO 2004-US724

20040114

W: AE, AE, AG, AL, AL, AM, AM, AM, AT, AT, AU, AZ, AZ, BA, BB, BG, BG, BR, BR, BW, BY, BY, BZ, BZ, CA, CH, CN, CN, CO, CO, CR, CR, CU, CU, CZ, CZ, DE, DE, DK, DK, DM, DZ, EC, EC, EE, EE, EG, ES, ES, FI, FI, GB, GD, GE, GE, GH, GM, HR, HR, HU, HU, ID, IL, IN, IS, JP, JP, KE, KE, KG, KG, KP, KP, KR, KR, KZ, KZ, KZ, LC, LK, LR, LS, LS, LT, LU, LV, MA, MD, MD, MG, MK, MN, MW, MX, MX, MZ, MZ, NA, NI

PRAI WO 1999-US31169

A2 19991230

US 2000-610635

B2 20000705

US 2001-899732

A2 20010705


US 1998-224426

A2 19981231

US 2003-341751

A 20030114

GI



AB This invention provides an isolated nucleic acid encoding a human MCH1 receptor, a purified human MCH1 receptor, vectors comprising isolated nucleic acid encoding a human MCH1 receptor, cells comprising such vectors, antibodies directed to a human MCH1 receptor, nucleic acid probes useful for detecting nucleic acid encoding human MCH1 receptors, antisense oligonucleotides complementary to unique sequences of nucleic acid encoding human MCH1 receptors, transgenic, nonhuman animals which express DNA encoding a normal or mutant human MCH1 receptor, methods of isolating a human MCH1 receptor, methods of treating an abnormality that is linked to the activity of a human MCH1 receptor, as well as methods of determining binding of compds. to mammalian MCH1 receptors. This invention further provides a method of treating a subject suffering from urinary incontinence which comprises administering to the subject an amount of an MCH1 antagonist effective to treat the subject's urinary incontinence or overactive bladder. Various 4-phenylpiperidine derivs., e.g (I), were synthesized and tested as human MCH1 receptor antagonists.



AN 2003:42108 CAPLUS  
 DN 138:106601  
 TI Preparation of substituted anilinic piperidines as MCH selective antagonists  
 IN Marzabadi, Mohammad R.; Wetzel, John; Deleon, John E.; Jiang, Yu  
 PA Synaptic Pharmaceutical Corporation, USA  
 SO PCT Int. Appl., 771 pp.  
 CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003004027	A1	20030116	WO 2002-US21063	20020703
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	EP 1411942	A1	20040428	EP 2002-746843	20020703
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
	BR 2002010869	A	20040629	BR 2002-10869	20020703
	JP 2004536104	T2	20041202	JP 2003-510038	20020703
	US 2004073036	A1	20040415	US 2003-345063	20030114
	US 2004186103	A1	20040923	US 2004-753057	20040106
PRAI	US 2001-899794	A	20010705		
	US 2002-42582	A	20020109		
	WO 2002-US21063	W	20020703		
	US 2003-345063	A2	20030114		
OS	MARPAT	138:106601			
GI					



AB The title compds. [I (R1 = H, alkyl, aryl, etc.; R2 = alkyl, cyclopropyl; R3 = (un)substituted (hetero)aryl; A = H, F, Cl, Br, CN, etc.; X = O, NH; n = 0-5), II (R1 = (un)substituted (hetero)aryl; R2, A, n as above ), etc.] which are selective antagonists for melanin concentrating hormone-1 (MCH1) receptors, were prepared and formulated. Thus, reacting 2-methyl-N-[3-(4-piperidinyl)phenyl]propanamide (preparation given) with 4-chloro-3',4'-dimethylbutyrophene in the presence of K2CO3 and NaI in DMF afforded 80% II [R1 = R1 = 3,4-Me2C6H3; R2 = iso-Pr; A = H; n = 2] which showed Ki of 3.9 nM in cloned rat MCH1 binding assay.

RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2004 ACS on STN  
AN 2002:793613 CAPLUS  
DN 137:310934  
TI Preparation of piperidinyl-, piperazinylcarboxamides as lipid lowering agents  
IN Meerpoel, Lieven; Viellevoye, Marcel  
PA Janssen Pharmaceutica N.V., Belg.  
SO PCT Int. Appl., 64 pp.  
CODEN: PIXXD2  
DT Patent  
LA English  
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2002081460	A1	20021017	WO 2002-EP3491	20020327
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2441398	AA	20021017	CA 2002-2441398	20020327
EE 200300488	A	20031215	EE 2003-488	20020327
EP 1379515	A1	20040114	EP 2002-722278	20020327
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
BR 2002008688	A	20040309	BR 2002-8688	20020327
NZ 528445	A	20040326	NZ 2002-528445	20020327
JP 2004525176	T2	20040819	JP 2002-579448	20020327
NO 2003004474	A	20031204	NO 2003-4474	20031006
PRAI EP 2001-201270	A	20010406		
WO 2002-EP3491	W	20020327		
OS MARPAT 137:310934				
GI				



\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

AB Title compds. I [r,s,q = 1-3; p = 0-1; R1 = H, alkyl, alkyloxy, halo, hydroxy, mercapto, cyano, nitro, etc.; R2 = H, alkyl, alkyloxy, halo, CF3; R3 = H, alkyl; R4 = alkyl, alkyloxy, halo, CF3; Z = e.g., -X1(R5)-(CH2)n-X2(R6)-; n = 2-4; R5-6 = H, alkyl, aryl; X1-2 = CH, N, sp2

hybridized carbon, etc.; A = bond, alkanediyl, etc.; B = e.g., R8-OCO-alkanediyl-Y-; Y = O, amino, etc.; R8 = alk(en/yn)yl, etc.] were prepared. For instance, N-[4-(1-piperazinyl)phenyl]-4'-(trifluoromethyl)[1,1'-biphenyl]-2-carboxamide (preparation given) was reacted with  $\alpha$ -chlorobenzeneacetic acid 2-methoxy-2-oxoethyl ester (preparation given, DMF, Na<sub>2</sub>CO<sub>3</sub>) to afford, after purification, II, m.p. 106°. II inhibited microsomal triglyceride transfer protein (MTP) activity with pIC<sub>50</sub> = 6.591. I are useful for the treatment of hyperlipidemia, obesity and type II diabetes.

RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4	ANSWER 5 OF 5	CAPLUS	COPYRIGHT 2004 ACS on STN	
AN	2002:71877	CAPLUS		
DN	136:134783			
TI	Preparation of piperazine(or piperidine)-1-carboxamides as CCR5 modulators			
IN	Bondinell, William E.; Neeb, Michael J.			
PA	Smithkline Beecham Corporation, USA			
SO	PCT Int. Appl., 79 pp.			
	CODEN: PIXXD2			
DT	Patent			
LA	English			
FAN.CNT 3				
	PATENT NO.	KIND	DATE	APPLICATION NO.
PI	WO 2002005819	A1	20020124	WO 2001-US22529
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM		20010713	
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
	AU 2001080599	A5	20020130	AU 2001-80599
	EP 1313477	A1	20030528	EP 2001-958995
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR		20010713	
	US 2004038982	A1	20040226	US 2003-343880
PRAI	US 2000-218509P	P	20000715	20030205
	WO 2001-US22529	W	20010713	
OS	MARPAT 136:134783			
GI				



AB The title compds. [I; the basic N atom in moiety E may be optionally quaternized with alkyl or optionally present as the N-oxide; A = (un)substituted (hetero)aryl or (hetero)aryl fused to a saturated or partly unsatd. 5-7 membered ring; D = a bond, CO, SO<sub>2</sub>, etc.; E1G = NC(R26)<sub>2</sub>, NC(R26)2C(R26)2, CR27C(R26)2, C:CR26; R26 = H, alkyl; R27 = H, CN, NO<sub>2</sub>, etc.; R = H, alkyl, O; J = CO, SO<sub>2</sub>; L = NR30, O, C(R30)<sub>2</sub>; R30 = H, alkyl; E = 3-(2-diisopropylamino)ethoxy-4-methoxyphenyl, etc.] which are modulators, agonists or antagonists, of the CCR5 receptor, and therefore are useful in the treatment and prevention of disease states mediated by CCR5, including, but not limited to, asthma and atopic disorders (for example, atopic dermatitis and allergies), rheumatoid arthritis, sarcoidosis, or idiopathic pulmonary fibrosis and other fibrotic diseases, atherosclerosis, psoriasis, autoimmune diseases such as multiple sclerosis, treating and/or preventing rejection of transplanted organs, and inflammatory bowel disease, were prepared. Thus, treating 4-phenyl-1,2,3,6-tetrahydropyridine.HCl with triphosgene in the presence of Et<sub>3</sub>N in CH<sub>2</sub>Cl<sub>2</sub> followed by addition of 3-(2-diisopropylamino)ethoxy-4-methoxyaniline afforded II. The compds. I showed CCR5 receptor modulator activity having IC<sub>50</sub> values in the range of 0.0001-100 μM. Furthermore, since CD8+ T cells have been implicated in COPD, CCR5 may play a role in their recruitment and therefore antagonists to CCR5 could provide potential therapeutic in the treatment of COPD. Also, since CCR5 is a co-receptor for the entry of HIV into cells, selective receptor modulators may be useful in the treatment of HIV infection.

RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT